Biomarkers and Therapeutic Targets in Inflammatory Breast Cancer (IBC)

Tiffany Avery, Massimo Cristofanilli*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Inflammatory breast cancer (IBC) is the most aggressive type of breast cancer with survival rates far lower than other types of breast cancer. Patterns of development, invasion, and presentation are unique to IBC compared with other breast cancers. However, therapies targeted specifically to the treatment of IBC are lacking. Specific therapies, which address the unique features of IBC, are needed to improve prognosis for this type of breast cancer. The first step in developing improved treatments is to identify biomarkers and genes, which are preferentially expressed in IBC and to develop therapies targeted to these markers. In this paper, we discuss advances made in the studies of biomarkers and gene expression in IBC over the last 5 years. Some of the markers have proven to be prognostic or predictive of response to therapy. In some cases, therapies targeted for biomarkers are already used in the treatment of cancer and could be evaluated in IBC patients.

Original languageEnglish (US)
Pages (from-to)245-250
Number of pages6
JournalCurrent Breast Cancer Reports
Issue number4
StatePublished - Nov 25 2014


  • Biomarkers
  • Gene expression
  • Inflammatory breast cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Biomarkers and Therapeutic Targets in Inflammatory Breast Cancer (IBC)'. Together they form a unique fingerprint.

Cite this